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Abstract - Overwhelming post-splenectomy infection 
(OPSI) is a rare medical emergency, mainly caused by 
encapsulated bacteria, shortly progressing from a mild flu-
like syndrome to a fulminant, potentially fatal, sepsis. The 
risk of OPSI is higher in children and in patients with 
underlying benign or malignant hematological disorders.   
We retrospectively assessed OPSI magnitude in a high 
risk cohort of 162 adult splenectomized patients with 
malignant (19%) and non malignant (81%) hematological 
diseases, over a 25-year period: 59 of them splenectomized 
after immunization against encapsulated bacteria, and 103, 
splenectomized in the previous 12-year study, receiving only 
life-long oral penicillin prophylaxis. The influence of 
splenectomy on the immune system, as well as the incidence, 
diagnosis, risk factors, preventive measures and 
management of OPSI are also outlined.    
OPSI occurred in 7 patients (4%) with a median age of 
37 years at time interval from splenectomy ranging from 10 
days to 12 years.  All OPSIs occurred in non immunized 
patients, except one fatal Staphylococcus aureus-mediated 
OPSI in a patient adequately immunized before 
splenectomy.  
Our analysis further provides evidence that OPSI is a 
lifelong risk and that current immune prophylaxis 
significantly decreases OPSI development. 
Improvement in patients’ education about long-term risk 
of OPSI and increased physician awareness to face a 
potentially lethal medical emergency, according to the 
current surviving sepsis guidelines, represent mandatory 
strategies for preventing and managing  OPSI appropriately. 
Keywords: Overwhelming postsplenectomy infection 
(OPSI) syndrome, splenectomy, hematological disorders 
 
I.  INTRODUCTION 
 
 The spleen, through its two main compartments 
called red and white pulp, is the largest secondary 
lymphoid organ dedicated to the blood filtering of old or 
damaged blood cells and foreign pathogens as well as to 
the immune surveillance and response to infections. 
Although, rapid removal of infectious agents from 
circulation by red pulp of the spleen is the prerequisite for 
successful control of infection, the key events responsible 
for initiating host defence against pathogens are 
developed in sub-compartments of white pulp distributed 
along central arterioles, including the periarteriolar 
lymphoid sheaths (PALS), follicles, and marginal zone 
(Figure 1, Table 1) [1-6].  
The splenic marginal zone (MZ) is the boundary 
between the red and white pulp where the terminal 
arterioles open into sinuses and the blood flow is slowed 
down, favouring early trapping of blood-borne bacteria, 
viruses, parasites, and other soluble and particulate 
antigens by dendritic cells, metallophilic macrophages 
and MZ macrophages [7].  Splenic MZ macrophages are 
highly phagocytic cells and are responsible for rapid 
clearance of blood-borne T-independent antigens and 
debris, by virtue of expressing an array of receptors 
promoting efficient antigen uptake detecting invading 
pathogens either directly or through intermediate opsonins 
[7-10]. Pathogen-recognition-receptors (PRRs), mediating 
opsonin-independent phagocytosis by splenic MZ 
macrophages, include Toll-like receptors, C-type lectins, 
type I and II scavenger receptors, macrophage receptors 
with collagenous structure, CD36, the mannose receptor 
and others [4,7,11,12].  Deficit of these PRRs increases 
susceptibility to a variety of viral, bacterial and mould 
infections [13-15].  Splenic MZ macrophages are also 
involved in opsonin-dependent phagocytosis, via natural 
antibodies and components of the complement system, 
which plays a critical role in the early control of bacterial 
and viral infections [16,17].   In addition, splenic MZ 
macrophages cooperate to deliver antigen presentation to 
T-cell areas (necessary for triggering protective T cell 
responses) [7,9] such as PALS and a thin layer 
surrounding  B-cell follicles, formed by an outer mantle 
zone containing dominantly proliferating small B 
lymphocytes and a central germinal center where B-cell 
selection occurs [2,4,6]. 
Several lines of evidence link a reduced antigen trapping 
by the splenic MZ macrophages to an impairment of early 
control of infection enhancing spread of the pathogens 
into circulation and organs [18].  Moreover, the human 
splenic MZ is a unique B-cell compartment containing a 







) “memory” B cells, carrying a 
mutated immunoglobulin receptor, distinct from the 
classical germinal center–derived memory B cells, which 
can be rapidly mobilized and activated to secrete Ig in 
response to blood-borne T-independent antigens [19-22].  
However, MZ B cells have also been shown to contribute 
to the generation of T cell-dependent antibody responses 
(Figure 1, Table 1) [9,23]. The result of this complex 
cross talk between white and red pulp as well as B and T 
cell areas of white pulp, linking innate and adaptive 
immune response, is thought to predominantly contribute 
to the sepsis-protective effect of the spleen [9,24]. 
Translational Medicine @ UniSa, - ISSN 2239-9747 2013, 6(2): 2-10 
 
3 
Università degli Studi di Salerno 
 
Figure 1. Antimicrobial splenic functions.  Compartments of white pulp involved in protective antimicrobial functions: a) periarteriolar lymphoid 
sheats (PALS) through  secretion of T-dependent immunoglobulins (Ig) and  antigen presentation to T-Lymphocyte by marginal zone (MZ) 
macrophages; b) follicles through  MZ macrophage-mediated activation of B lymphocytes and plasmacells and  production of antibodies, 
complement and opsonins;  c) marginal zone through  opsonin-independent phagocytosis mediated  by MZ macrophages,   presentation of 
particulate antigens by MZ macrophages to CD27+IgM+ B cells,  rapid release of antibodies by CD27+IgM+ memory B cells,  opsonin-
dependent phagocytosis by MZ macrophages. Red pulp exerts anti-microbial protective functions mainly through  blood-borne pathogens filtering, 
culling and pitting of red blood cells (RBC) and  rapid GM-CSF release via innate response activator (IRA) and antibodies by B cells and 
plasmacells.  
Symbols: Ig = ; T-cell receptor/Major hystocompatibility complex binding,  ; complement , ;opsonin, ;  pathogen-recognition-receptors 
(PRRs), ; particulate antigen, ; GM-CSF (Granulocyte-macrophage colony-stimulating factor), . 
 
Overwhelming post-splenectomy infection (OPSI) is 
a rare fulminant sepsis with a mortality up to 70% [25-
27].  An underlying hematological disease and conditions 
eliciting immunosuppression are associated with higher 
OPSI rate and mortality, with thalassemic and 
drepanocytic patients having the highest rates of 
infections (8.2% and 7.3%) and mortality (5.1% and 
4.8%), respectively [16,28].  OPSI and mortality rate in 
splenectomized patients for autoimmune thrombo-
cytopenia are similar to that for trauma (about 2.3% and 
1.2%,) and lower than that for Hodgkin's disease (4.1% 
and 1.9%), and spherocytosis (3.1% and 1.3%) [28].   
Apart from splenectomized subjects, higher rate of 
infections have been also reported in diseases associated 
with splenic atrophy or hyposplenism, such as celiac 
disease, Crohn’s disease, sickle cell anemia, 
spherocytosis, chronic graft versus host disease, systemic 
lupus erythematosus, HIV infection, amyloidosis and 
several other disorders  (Table 2) [1,6].  The cumulative 
risk for asplenic and hypospenic patients to develop an 
OPSI is estimated to be about 1 per 500 patients per year 
[26,29]. 
Although the risk of infections declines with the time 
elapsed following splenectomy, with up to 50% of cases 
occurring within 2 years after surgery,  30-40% of  OPSI 
have been  documented > 5 years  and  individual cases 
even more  than 40  years  post-splenectomy, indicating  a 




PROTECTIVE ANTIMICROBIAL FUNCTIONS OF THE SPLEEN 
 
 Pulp Functions 
 Red  - Blood-borne pathogens filtering  
- Culling and pitting of red blood cells 
- Rapid GM-CSF release via IRA 




Periarteriolar lymphoid sheath (PALS): 
- Antigen presentation to T-lymphocytes by MZ macrophages 
- T-dependent Ig secretion 
Follicles: 
-  Storage and maturation  of B lymphocytes 
-  Antibodies release by B lymphocytes 
-  Production of complement, opsonins, properdin  and tuftsin  
Marginal zone: 
- Antigen presentation by MZ macrophages to CD27+IgM+ B 
cells 
- Trapping of pathogens by MZ dendritic cells, metallophilic 
and MZ macrophages 
- Opsonin-dependent phagocytosis via complement and 
antibodies by MZ macrophages  
- Opsonin-independent phagocytosis via PRRs by MZ 
macrophages 
- Rapid clearance of blood-borne T-independent antigens 
- Rapid release of antibodies by CD27+IgM+ B cells 
Abbreviations. GM-CSF =  granulocyte - macrophages colony - 
stimulating factor; IRA = innate response activator; MZ = marginal 
zone; CD = cluster of differentiation; Ig = immunoglobulins; PRRs = 
pathogen-recognition-receptors.  
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Most OPSI are caused by encapsulated bacteria such 
as Streptococcus pneumoniae (involved in more than 50% 
of cases), Haemophilus influenzae, Neisseria meningi-
tidis, but also by intraerythrocytic parasites or bacteria 
mainly removed by the spleen, such as Babesia, Ehrlichia 
and Plasmodia [19,26,29,31-33]. Enterococcus, Bacte-
roides, Salmonella and Bartonella species have occasion-
nally been reported responsible for OPSI [31]. Recently, 
OPSI cases due to the Gram negative bacterium 
Capnocytophaga canimorsus, transmitted through dog, 
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Early stage of OPSI is usually characterized by 
aspecific symptoms similar to those of a flu-like 
syndrome quickly progressing to symptoms of a 
bacteremic septic shock, including hypotension, acidosis, 
electrolytic disorder, hypoglycemia, oliguria, respiratory 
distress, cardio-vascular collapse, convulsions, 
disseminated intravascular coagulopathy (DIC) and multi-
systemic organ failure. Coma and death can occur within 
24 to 72 hours of illness onset [19,25].  Children more 
frequently than adults have concomitant pneumonia and 
meningitis [35].  
Supporting laboratory evidences of OPSI, apart from 
those specifically related to the bacteremic septic shock, 
DIC and  multi-system organ failure, include the presence 
of Howell-Jolly bodies in erythrocytes [6,19,34,36] 
(Figure 2), and of pitted erythrocytes [5,19,37]. 
 
Figure 2. Howell-Jolly bodies. Howell-Jolly bodies (red arrows) in 
circulating red blood cells of a patient with OPSI. 
 
Other investigations useful for splenic function 
assessment, such as scintigraphic and immunological 
parameters, detailed in Table 3, are limited by their 
technical difficulties in critically ill patients, such as those 
suspected of  having a OPSI [6,19,37-38].  
 
TABLE 3 
DIAGNOSTIC TECNIQUES ASSESSING SPLENIC FUNCTION 
  
- Detection of circulating Howell-Jolly bodies on stained blood films 
- Detection of pitted erythrocytes by phase-interference microscopy  
- Detection of B cells CD27+IgM+ decrease by flow-cytometry  
- Technetium-99m-labelled sulphur colloidal scintiscan 
- Clearance of Technetium-99m-labelled or rubidium -81-labelled 




II.  METHODOLOGY 
 
Subjects 
We have conducted a retrospective evaluation of 
adult patients who were splenectomized (n=162) over a 
25-year period for hematological diseases (Table 4). A 
few cases of splenectomy in children are reported in our 
survey (11 cases < 15 years),  coming to our attention 
months or years after surgery.  Informed consent was 
obtained from all patients in accordance with institutional 
guidelines and the study design was made in accordance 
with the Helsinki II Declaration [39].  
The age at splenectomy ranged between 11 and 60 
years (mean±SD, 37±22 years) and their post-
splenectomy follow-up lasted from 1 to 300 months 
(mean±SD, 150±12 months).  Primary diseases were 
immune thrombocytopenia (ITP; n=86), Hodgkin and non 
Hodgkin’s lymphoma (HD/NHL; n=22), warm antibody 
autoimmune hemolytic anemia (wAIHA; n=14), 
hereditary spherocytosis (HS; n=10), Cooley’s disease 
(n=10), congenital non-spherocytic hemolytic anemias 
(CNSHAs; n=5), idiopathic myelofibrosis (IMF; n=5), 
hairy cell leukemia (HCL; n=4), -thalassemia intermedia 
(n=4) and sickle cell anemia (n=2).  In adult ITP, most of 
Translational Medicine @ UniSa, - ISSN 2239-9747 2013, 6(2): 2-10 
 
5 
Università degli Studi di Salerno 
splenectomy (76% of cases) was performed on adults who 
did not respond to two courses of glucocorticoid treatment 
or who continued to require high–dose steroids to achieve 
a safe platelet count.  In the remaining and more recent 
ITP cases, although the correct positioning of rituximab or 
thrombopoietin receptor agonists for the management of 
chronic ITP before splenectomy is not yet clear, surgery 
was performed after the failure of such therapies for 
refusal of patients to undergo surgery as second or third-
line therapy [30,40-43].  In wAIHA, splenectomy was 
performed long time after the beginning of the disease (at 
least 1 year) in patients with refractory or recurrent 
disease after immunosuppressive therapies including 
steroids, azathioprine, cyclophosphamide, rituximab, and 
requiring high maintenance steroid doses to achieve an 
acceptable hemoglobin value [30,45-47].  In these 
wAIHA, splenectomy was performed only after 
measurement of 
51
Cr-red blood cell sequestration in the 
spleen [48].  The majority of cases of splenectomy for 
thalassemia and hemoglobinopathies, including  Cooley’s 
disease, intermediate thalassemia and sickle cell anemia, 
refer to patients who already underwent surgery in 
pediatric age for progressive increase in transfusion 
requirement and difficulty to control iron overload 
[32,49].  In hereditary spherocytosis and other CNSHAs, 
including pyruvate kinase deficiency, splenectomy was 
performed when patients had moderate/severe anemia 
[50-51].  In CNSHAs, like in wAIHA, also splenectomy 
was performed only after measurement of 
51
Cr-red blood 
cell  sequestration in the spleen [48]. In 22 patients with 
HD and NHL, splenectomy was mainly diagnostic, in few 
HD and NHL cases also therapeutic [52].  Four patients 
with HCL were splenectomized in pre-interferon and 
cladribrine era when they suffered from moderate/severe 
hypersplenism-related pancytopenia [53].  Splenectomy 
was performed in 5 selected IMF patients showing 
heavily symptomatic splenomegaly refractory to drug 









Hodgkin’s and non-Hodgkin’s lymphoma 
Warm antibody autoimmune hemolytic anemia 
Hereditary spherocytosis 
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Congenital non-spherocytic hemolytic anemias 
Idiopathic myelofibrosis 
Hairy cell leukemia 
Thalassemia Intermedia 











                                                                   Total 162 
 
Open surgery was conducted in 105 patients, while 57 




Antibiotic prophylaxis and immunization  
Prophylactic oral penicillin was prescribed to all 
splenectomized patients for the first two years after 
splenectomy or up to age 16 [6,19,55-58].  
Before or within 2 weeks from surgery, when specific 
vaccines were commercially available, immunization 
against Streptococcus pneumoniae, Haemophilus 
influenzae type b (Hib) and Neisseria meningitidis were 
carried out using the 23-valent pneumococcal 
polysaccharide vaccine (23vPVV), Hib protein–
polysaccharide conjugate vaccine and 4-valent 
meningococcal polysaccharide vaccine (4vMenPV), 
respectively [6,19,55-57,59-61].  
 
Statistical analysis 
All data were collected from a computerized database 
and chart reviews were analysed  using GraphPad Prism 
version 5. A P value ≤.01 was considered to be 





Patients characteristics  
A retrospective observational study evaluating OPSI 
development rate was performed in 162 adult patients 
which underwent splenectomy for malignant (19%) and 
non malignant (81%) hematological diseases over a 25-
year period. Most of the patients (n=99, 61%) in our 
survey underwent splenectomy within the first 12 years of 
the study.  Forty-seven percent of splenectomized patients 
had a higher risk of developing OPSI, since they were 
splenectomized for hematological disorders associated 
with severe impaired immunity such as thalassemia or 
sickle cell anemia (10%), hereditary spherocytosis or non-
spherocytic anemia (9%), autoimmune hemolytic anemia 
(7%), malignant lymphoproliferative and myeloprolifera-
tive diseases (19%) (Table 4).  
It has been reported that the infection risk and death 
rates for ITP patients is similar to those who underwent 
splenectomy for trauma [41].  However,  almost all our 
ITP patients were heavily immunosuppressed, since they 
underwent surgery only after refractoriness to at least 
two-three courses of immunosuppressive therapy with at 
least two different drugs or who continued to require 




All splenectomized patients received oral penicillin 
antibiotic prophylaxis for the first two years after 
splenectomy or up to age 16.  In addition, life-long 
prophylactic oral penicillin was offered to all 
immunosuppresed patients,  but not all of these patients 
have taken it either due to intolerance or refusal to 
perform it continuously. 
Vaccine prophylaxis against Streptococcus 
pneumoniae was performed in 59 (36%) patients (ITP, 
n=35; HD/NHL, n=6; wAIHA n=5; HS, n=5; Cooley's 
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disease, n=3; CNSHA, n=1; IMF, n=2; Thalassemia 
intermedia, n=2),  associated with simultaneous 
immunization against Hib and Neisseria meningitidis in 
42 patients (26%) (ITP, n=30; wAIHA n=2; HD, n=2; HS, 
n=5; Cooley's disease, n=3) (Table 4). 
 
OPSI  
OPSI occurred in 7 patients (4%) with a median age 
of 37+22 years and an age range from 16 to 60 years 
(Table 5).  All patients had high risk disease for OPSI 
including 2 cases with lymphoma, 2 with thalassemia 
intermedia, 2 with Cooley’s disease, and 1 with long-
lasting warm antibody auto-immune hemolysis.  The 
interval from splenectomy to OPSI varied from 10 days to 
12 years with 3 OPSI (43%) occurring shortly post-
splenectomy (from 10 to 25 days) and 4 OPSI (57%) >5 
years post-splenectomy (from 5 to 12 years, respectively) 
(Table 5) . 
In all OPSI, the onset of symptoms was mild, like a 
flu-like syndrome, followed by high fever (even without 
fever in a case of wAIHA), and by septic shock and DIC 
leading within 2-5 days to death in 6 out of 7 cases (85%) 
from an apparent good health. Only a 17 years-old female 
with Cooley's disease survived from a group A 
Streptococcus-mediated OPSI developing 7 years post-
splenectomy.  She recovered following immediate transfer 
to an intensive care unit where she was treated with 
prolonged ceftriaxone and vancomycin therapy combined 
with aggressive management of shock and DIC; currently, 




OVERWHELMING SEPSIS AND THROMBOTIC EVENTS AFTER 
SPLENECTOMY 
 
Event Age Disease Timing     

































10 days       
10 days       
25 days       
12  years     
5  years       
6  years       
 8  years       
3  years       
2 months    











Abbreviations. OPSI = overwhelming post-splenectomy infection; 
HD = Hodgkin’s disease; NHL = non Hodgkin’s lymphoma; Th.Int. = 
thalassemia intermedia; wAIHA = warm antibody autoimmune 
hemolytic anemia; IMF = idiopathic myelofibrosis; ITP = immune 
thrombocytopenia. 
 
All OPSI occurred in non immunized patients except 
a OPSI case with a 10-year history of wAIHA, who 
carried out a pre-splenectomy vaccination program with 
both anti-pneumococcal and anti-meningococcal vaccines, 
as well as with anti-Hib vaccine.  Apart from this last 
OPSI, where a Staphylococcus aureus bacteremia was 
detected and the above mentioned group A 
Streptococcus–mediated OPSI,  in all other OPSI cases 
(71%) a pneumococcal bacteriemia was documented. 
 
Thromboembolic complications  
Patients undergoing splenectomy for hematologic 
disorders have an increased risk of vascular complications 
[30,44].  In our survey, we have registered 2 fatal vascular 
complications, both after open splenectomy: the first one 
in a 41 year old ITP female with delayed signs of 
mesenteric thrombosis and the second one in a 50 year old 
IMF male with signs of pulmonary hypertension as a 
result of in situ thrombosis.  A 49 year old male, with 
acute pulmunary thromboembolism, requiring 
thrombolytic therapy and systemic anticoagulation during 
59 days of hospitalization, followed by oral 
anticoagulation for 6 months, is currently well 5 years 





Splenectomy provides a high rate of complete 
response for patients with immune thrombocytopenia [41-
42] and can ameliorate the underlying anemia in a variety 
of other benign hematological disorders including 
hemolytic anemia, hereditary spherocytic and non 
spherocytic hemolytic anemias, Cooley’ diseases, 
thalassemia intermedia and sickle cell anemia [30,45-51].  
In addition, splenectomy still remains an useful approach 
for the diagnosis and for relieve symptoms of 
hypersplenism and splenomegaly in several malignant 
hematological diseases such as lymphomas and chronic 
myeloproliferative syndromes (Table 2) [52-54].  
Life-threatening infections and thromboembolic 
events represent the major short- and long-term 
postoperative complications after splenectomy [30,44]; 
additionally, severe infections may affect clinical course 
of several functional hyposplenisms (Table 2) [1,6].  
OPSI, a rare clinical infectious syndrome, affecting  
about 3% of splenectomized patients, is a serious medical 
emergency shortly progressing to a fulminant sepsis 
mainly by encapsulated bacteria [19,26,31-33], carrying a 
high mortality rate (>50%) [16,26,28-29].  
The major documented risk factors for OPSI 
development in asplenic patients are younger age,  
underlying diseases, previous and concomitant 
immunosuppression and time from splenectomy [34].  
Splenectomy is usually postponed until the child is 6 
year old, due to spleen immaturity in the first 5 years of 
age, mainly related to low levels of opsonin- and IgM 
memory B cells responsible for phagocytosis of 
encapsulated bacteria [37].  Although in our series, 
children suffering from hereditary hematological 
disorders underwent splenectomy when they were more 
than 5 year-old, we registered in the pre-vaccination era, 3 
fatal OPSI despite they had been receiving life-long 
antibiotic prophylaxis, and careful quantification of 
Howell-Jolly bodies on peripheral blood films during the 
whole follow-up [36].  
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Early increase of circulating Howell-Jolly bodies and 
pitted erythrocytes after splenectomy are historically 
associated, when their percentage is more than 8%, with 
significant splenic dysfunction [36-37]. Recently, 






 “memory” B 
cells has also been proposed as an assay to assess asplenic 
populations at risk for OPSI.  However, although IgM 
memory B cells gradually decrease within 6 months after 
splenectomy achieving reduced stable levels up to more 
than 2 years, no association of levels of IgM memory B 
cells with the underlying indication for splenectomy and 
infections has been reported [20-21].  
In our cohort of 162 high risk splenectomized patients 
for malignant (19%) and non malignant (81%) 
hematological disorders, OPSI occurred in 4% of cases 
with a median age of 37+22 years.  
Previous reports have consistently documented  that 
the highest risk of infections following splenectomy, is 
within the first two years after surgery.  In our series, 
OPSI occurred early (within 1 month) in 43% of cases 
and late (over 5 years, 57%) in the remaining, further 
indicating a long-lasting OPSI risk in these patients 
(Table 5).  In accordance with literature, we also 
documented that the most frequent etiologic agent 
responsible for OPSI was the Streptococcus pneumoniae  
(70% of cases)  [19,26,31]. 
Various guidelines for the prevention of sepsis in 
asplenic patients exist in the literature; these 
recommendations are based on immunization against S. 
pneumoniae, N. meningitidis, H. influenzae type b, 
lifelong antibiotic prophylaxis in high risk patients 
[6,19,55-57,59-61], and education of patients and health 
professionals to prevents infections [6,62-64].  
Since in our survey, 70% of hematological patients 
underwent splenectomy within the first 12 years of the 
study, a time when the current polyvalent pneumococcal 
vaccine was not commercially available, only 35% of 
them underwent surgery prior to anti-pneumoccoccal 
vaccination, associated with simultaneous anti-
meningococcal and anti-influenza type B immunization in 
25% of cases.  In our series, OPSI development among 
patients immunized and those not receiving vaccinations 
significantly decreased (from 5% to 1.7%, respectively; 
p<.01).  Recently, an increasing number of OPSI cases 
caused by pathogens not covered by vaccinations or 
resistant to antibiotic prophylaxis has been reported 
[17,19,26,29,31-34].  In our series, we documented a case 
of fatal Staphylococcus aureus-mediated OPSI in a patient 
who had undergone a complete pre-splenectomy 
vaccination program, according to the current guidelines. 
Although the introduction of an adequate vaccination 
program against encapsulated bacteria and systematically 
oral penicillin prophylaxis have decreased the overall risk 
of OPSI, its mortality rate remains high, ranging from 
50% to 70% within 48 h [55].  
OPSI, once triggered, is a serious medical emergency 
requiring immediate therapeutic administration of 
antimicrobial agents and aggressive care support 
according to surviving sepsis campaign guidelines for 
management of severe sepsis and septic shock,  even 
before any diagnostic test result performed upon 
admission comes back from laboratories [25,63].  
Observational evidences have documented that early 
aggressive antimicrobial therapy combined with intensive 
care support may decrease  the mortality rate for OPSI as 
low as 10% [25].  
Thromboembolic complications following 
splenectomy for hematological diseases represent another 
short- and long-term life-threatening complication of 
splenectomy;  they occurs in up to 10% of these patients, 
more frequently among myeloproliferative and hemolytic 
patients, ranging from portal vein thrombosis to 
pulmonary embolism [30,44]. In our series, we 
documented 3 severe thromboembolic events: two of 
them shortly and one after a prolonged time interval (3 
years) after surgery for IMF and ITP, respectively.  
Recently, Crary et al. [64-66] as well as Di Sabatino et al. 
[6] reviewed this issue addressing specific 
recommendations for post-splenectomy thromboembolism 
prevention and management. 
Increased awareness that splenectomized patients face 
lifelong risk of OPSI and vascular complications, have led 
to a more conservative approach, resulting in a significant 
decrease of splenectomies in the last 15 years for 
emergency, especially for treatment of benign 
hematologic disorders [44]. In our series of adult 
hematologic patients,  only 59 of them underwent  
splenectomy in the last 12 years.    
In addition, various surgical techniques of partial 
splenectomy, preserving 10-20% of functional splenic 
tissue, have been recently adopted, but their role on 






Splenectomy and hyposplenism are associated with 
multiple and complex abnormalities of innate and 
adaptive immune response, including mainly decreased 
filtering of blood-borne pathogens and T-dependent and 







memory B cells against encapsulated bacteria. Lifelong 
risk for overwhelming sepsis and, to a lesser extent, for 
thromboembolism remains major complications after 
splenectomy occurring irrespective of age and time 
interval after the surgical procedure.  
The risk of OPSI is higher in children less than 5 
years old, in those who have had immunosuppressive 
treatments as well as in patients suffering from a benign 
or malignant hematological disorder.   
Currently, the established standard of care for post-
splenectomy patients includes immunization with 
polyvalent pneumococcal vaccine, Haemophilus 
influenzae type b conjugate and meningococcal 
polysaccharide vaccine before or within 2 weeks from 
splenectomy, associated with  prophylactic penicillin, and 
patient education to alert physicians when fever occurs.   
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Despite the above mentioned preventive measures 
decreased the overall risk of OPSI, it is still associated 
with an unacceptably high mortality rate.   
Concerns about the highest OPSI mortality rate 
among hematologic patients and the increasing 
appearance of OPSI mediated by pathogens not covered 
by current vaccinations led to a more conservative 
approach through a reassessment of indications and 
timing of the surgery, given also the expanding arsenal of 
therapeutics available for treating hematological 
disorders.  Alternative methods for preventing post 
splenectomy sepsis, such as subtotal splenectomy, need to 
be confirmed in larger studies.  
Despite various limitations, including retrospective 
analysis, a small number of patients, especially in the 
group receiving the appropriate vaccination program, our 
study further provides evidence that OPSI is a lifelong 
risk and that immune prophylaxis against encapsulated 
bacteria significantly decreases OPSI development among 
hematological patients. 
Early identification and aggressive emergency 
treatment of OPSI with antimicrobial agents and intensive 
care support may positively affect outcomes of this 
fulminant and fatal  disease.  
Improvement of patients’ education about their 
asplenic or hyposplenic status and increased healthcare 
worker awareness about the potential fulminant 
progression of infections in splenectomized patients 
represent mandatory strategies for preventing and 
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